Olema Pharmaceuticals, Inc. OLMA 深 滬
等待開盤 11-26 09:30:00 美东时间
26.07
+1.020
+4.07%
華盛通- 最 高26.57
- 今 開25.05
- 成交量 378.04万股
- 最 低 24.76
- 昨 收 25.05
- 總市值 17.89亿
- 52周最高 27.17
- 市盈率 靜 --
- 換手率 5.51%
- 52周最低 2.86
- 委 比 -64.07%
- 總股本 6863.43万
- 歷史最高 60.27
- 量 比 0.15
- 振 幅 7.23%
- 歷史最低 2.00
- 每 手 1
- 風險率 3.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
美股周涨跌榜 | 社交电商平台WeShop上市一周涨超275%；精密科学周涨超50%，获雅培230亿美元收购
社交电商平台WeShop上市一周涨超275%；精密科学周涨超50%，获雅培230亿美元收购；SEMrush周涨近67%，获Adobe收购>>
11-22 10:30
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, announced its participation in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025. Live webcasts and recordings will be available on its investor relations website. The company is advancing therapies, including palazestrant (OP-1250) and OP-3136, for endocrine-driven cancers. Headquartered in San Fra...
11-21 21:30
美股盘前 | 锂矿概念股再度走强，SGML盘前飙升16%；普拉格能源盘前重挫超17%
锂矿概念股再度走强，SGML盘前飙升16%，美国雅保盘前涨超1%；普拉格能源盘前重挫超17%，公司宣布发行3.75亿美元可转换债券>>
11-19 17:23
美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
11-19 16:54
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
11-19 01:01
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $32
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target from $29 to $32.
11-18 23:38
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.
11-18 22:56
